Products
IFIT3 antibody
Category:
Research Area:
- SPECIFICATIONS
- Product Name
- IFIT3 antibody
- Catalogue No.
- FNab04138
- Size
- 100μg
- Form
- liquid
- Purification
- Immunogen affinity purified
- Purity
- ≥95% as determined by SDS-PAGE
- Clonality
- polyclonal
- Isotype
- IgG
- Storage
- PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
- Immunogen
- interferon-induced protein with tetratricopeptide repeats 3
- Alternative Names
- CIG-49 antibody, IFI60 antibody, IFIT4 antibody, ISG60 antibody
- UniProt ID
- O14879
- Observed MW
- 60 kDa
Application
- Tested Applications
- ELISA, WB, IHC, IP
- Recommended dilution
- WB: 1:500-1:1000; IP: 1:500-1:1000; IHC: 1:50-1:200
Validated Images
HepG2 cells were subjected to SDS PAGE followed by western blot with FNab04138(IFIT3 antibody) at dilution of 1:600
IP Result of anti-IFIT3 (IP: FNab04138, 3ug; Detection: FNab04138 1:500) with HepG2 cells lysate 1500ug.
Immunohistochemistry of paraffin-embedded human lung cancer tissue slide using FNab04138(IFIT3 Antibody) at dilution of 1:100
- Background
- IFN-induced antiviral protein which acts as an inhibitor of cellular as well as viral processes, cell migration, proliferation, signaling, and viral replication. Enhances MAVS-mediated host antiviral responses by serving as an adapter bridging TBK1 to MAVS which leads to the activation of TBK1 and phosphorylation of IRF3 and phosphorylated IRF3 translocates into nucleus to promote antiviral gene transcription. Exihibits an antiproliferative activity via the up-regulation of cell cycle negative regulators CDKN1A/p21 and CDKN1B/p27. Normally, CDKN1B/p27 turnover is regulated by COPS5, which binds CDKN1B/p27 in the nucleus and exports it to the cytoplasm for ubiquitin-dependent degradation. IFIT3 sequesters COPS5 in the cytoplasm, thereby increasing nuclear CDKN1B/p27 protein levels. Upregulates CDKN1A/p21 by downregulating MYC, a repressor of CDKN1A/p21. Can negatively regulate the apoptotic effects of IFIT2.